AI Engines For more Details: Perplexity Kagi Labs You
Asthma Treatment: Zileuton is primarily used for the management of asthma, particularly in cases where symptoms are not adequately controlled by other asthma medications such as bronchodilators or corticosteroids. It works by inhibiting the enzyme 5-lipoxygenase, which is involved in the production of leukotrienes, substances that contribute to inflammation and bronchoconstriction in the airways.
Improvement of Asthma Symptoms: Zileuton helps to reduce inflammation in the airways and decrease bronchoconstriction, leading to improved airflow and relief of asthma symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Prevention of Asthma Attacks: By reducing airway inflammation and constriction, zileuton helps to prevent asthma exacerbations and reduce the frequency and severity of asthma attacks. It is often used as a long-term maintenance treatment to control asthma symptoms and minimize the need for rescue medications.
Zyflo CR Formulation: Zyflo CR (controlled-release) is an extended-release formulation of zileuton that allows for once-daily dosing, providing continuous asthma symptom control throughout the day. This formulation may improve treatment adherence and convenience for patients.
Adverse Effects: Like any medication, zileuton may cause adverse effects in some individuals. Common side effects include headache, gastrointestinal disturbances (such as nausea, vomiting, diarrhea, and abdominal pain), liver function abnormalities (elevated liver enzymes), and insomnia. These side effects are usually mild to moderate in severity and often resolve with continued use or dose adjustment.
Liver Function Monitoring: Due to the risk of liver toxicity, liver function tests should be performed regularly during zileuton treatment to monitor for signs of liver dysfunction. Patients should be advised to report any symptoms of liver injury, such as jaundice (yellowing of the skin or eyes), dark urine, or abdominal pain, to their healthcare provider promptly.
Drug Interactions: Zileuton may interact with other medications, particularly those metabolized by the cytochrome P450 enzyme system. Concurrent use of zileuton with certain drugs, such as warfarin (an anticoagulant) or theophylline (a bronchodilator), may require dose adjustments or close monitoring to prevent adverse effects or drug interactions.
Contraindications: Zileuton is contraindicated in patients with active liver disease or liver function abnormalities. It should not be used in individuals with a history of allergic reactions to zileuton or any of its components.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.1 | 0.3 | 9.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 2.4 | 2.3 | 0.04 |
| Allergies | 4.1 | 2 | 1.05 |
| Allergy to milk products | 1.6 | 1.2 | 0.33 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.3 | 4.3 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 0.8 | 2.5 |
| Ankylosing spondylitis | 3.7 | 0.9 | 3.11 |
| Anorexia Nervosa | 0.9 | 2 | -1.22 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.3 | 2 |
| Asthma | 5.2 | 2.6 | 1 |
| Atherosclerosis | 1.6 | 1.1 | 0.45 |
| Atrial fibrillation | 2.2 | 1.5 | 0.47 |
| Autism | 6 | 6.9 | -0.15 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1.7 | 1.1 | 0.55 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 2.5 | -1.78 |
| Carcinoma | 3.7 | 1.9 | 0.95 |
| Celiac Disease | 1.6 | 3.3 | -1.06 |
| Cerebral Palsy | 1.5 | 1 | 0.5 |
| Chronic Fatigue Syndrome | 3.5 | 2.4 | 0.46 |
| Chronic Kidney Disease | 3.2 | 1.9 | 0.68 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.7 | 0.12 |
| Chronic Urticaria (Hives) | 1.8 | 0.4 | 3.5 |
| Coagulation / Micro clot triggering bacteria | 1.3 | 1 | 0.3 |
| Cognitive Function | 1.7 | 1.6 | 0.06 |
| Colorectal Cancer | 5.1 | 2.1 | 1.43 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 1.6 | 1.5 | 0.07 |
| COVID-19 | 6.4 | 6.5 | -0.02 |
| Crohn's Disease | 5.4 | 4 | 0.35 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1 | 1.6 | -0.6 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 1.3 | 1.1 | 0.18 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 8.6 | 6.6 | 0.3 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.6 | 0.06 |
| Endometriosis | 2.6 | 1.9 | 0.37 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.9 | 1.3 | 1.23 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.5 | 0.8 | 2.13 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 2.2 | 0.73 |
| gallstone disease (gsd) | 2.2 | 1.3 | 0.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.8 | -0.14 |
| Generalized anxiety disorder | 2.5 | 2 | 0.25 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 0.4 | 2.25 |
| Graves' disease | 1.2 | 2.7 | -1.25 |
| Gulf War Syndrome | 0.6 | 1 | -0.67 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 2.9 | 1.6 | 0.81 |
| Heart Failure | 2.6 | 1.2 | 1.17 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.2 | 0.3 | 3 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.4 | 1.25 |
| hyperglycemia | 2.8 | 1.3 | 1.15 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.3 | 2.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.6 | 4.2 | -0.17 |
| Hypothyroidism | 0.2 | 0.7 | -2.5 |
| Hypoxia | 2.6 | 0.3 | 7.67 |
| IgA nephropathy (IgAN) | 1.2 | 3 | -1.5 |
| Inflammatory Bowel Disease | 5.3 | 5.5 | -0.04 |
| Insomnia | 2.1 | 2.4 | -0.14 |
| Intelligence | 0.9 | 0.9 | |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 6.1 | 3.4 | 0.79 |
| ischemic stroke | 2.4 | 1.4 | 0.71 |
| Liver Cirrhosis | 6.3 | 4.7 | 0.34 |
| Long COVID | 5.1 | 5.5 | -0.08 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.3 | 1.1 | 0.18 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.3 | 2.33 |
| ME/CFS with IBS | 1 | 0.9 | 0.11 |
| ME/CFS without IBS | 0.9 | 1.3 | -0.44 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.7 | 0.7 | 1.43 |
| Metabolic Syndrome | 5.8 | 5.6 | 0.04 |
| Mood Disorders | 8.6 | 5.5 | 0.56 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 5.1 | 2.4 | 1.13 |
| Multiple system atrophy (MSA) | 0.8 | 0.4 | 1 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.9 | -5.33 |
| Neuropathy (all types) | 0.9 | 1.3 | -0.44 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5 | 3.6 | 0.39 |
| NonCeliac Gluten Sensitivity | 1.7 | 0.6 | 1.83 |
| Obesity | 7.6 | 7 | 0.09 |
| obsessive-compulsive disorder | 2.9 | 2.6 | 0.12 |
| Osteoarthritis | 1.9 | 1.1 | 0.73 |
| Osteoporosis | 2.2 | 1.7 | 0.29 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 6.3 | 4.5 | 0.4 |
| Polycystic ovary syndrome | 2.8 | 2.5 | 0.12 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2 | 0.5 | 3 |
| Psoriasis | 2.1 | 1.2 | 0.75 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.2 | 3.2 | 0.63 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 5.3 | 2.2 | 1.41 |
| scoliosis | 0.4 | 0.8 | -1 |
| Sjögren syndrome | 2.2 | 1.6 | 0.38 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.7 | 1.57 |
| Stress / posttraumatic stress disorder | 2.8 | 1.9 | 0.47 |
| Systemic Lupus Erythematosus | 2.9 | 1.9 | 0.53 |
| Tic Disorder | 0.6 | 1.2 | -1 |
| Tourette syndrome | 1.1 | 0.3 | 2.67 |
| Type 1 Diabetes | 2.8 | 3.3 | -0.18 |
| Type 2 Diabetes | 5.9 | 4.8 | 0.23 |
| Ulcerative colitis | 4 | 3.3 | 0.21 |
| Unhealthy Ageing | 3.4 | 1.3 | 1.62 |
| Vitiligo | 1.2 | 0.7 | 0.71 |
